Organic Process Research & Development 2010, 14, 242–243
Practical and Scalable Process for the Preparation of 4-Amino-1,3-dimethylpyrazole
Hydrochloride
Stephen R. Graham,*,† Peter J. Brown,† and J. Gair Ford*,‡
SAFC Pharma, Synergy House, Manchester Science Park, Manchester, U.K. M15 6SY, and Process R&D, AstraZeneca, Silk
Road Business Park, Charter Way, Macclesfield, U.K. SK10 2NA
Abstract:
A practical and scalable process for the preparation of
4-amino-1,3-dimethylpyrazole hydrochloride 1 is described.
Compound 1 is a useful starting material; its preparation is
achieved Wia a three-step sequence from methyl hydrazine
and technical grade acetaldehyde dimethylacetal. The target
molecule is isolated in high chemical and isomeric purity
(>99.0% with respect to 4-amino-1,5-dimethylpyrazole).
Figure 1. 4-Amino-1,3-dimethylpyrazole hydrochloride, 1, and
regioisomer 4-amino-1,5-dimethylpyrazole, 1a.
Introduction
The ability to rapidly prepare multikilogram quantities of
starting material, 4-amino-1,3-dimethylpyrazole hydrochloride,
1, would be advantageous. In order to achieve this, we have
developed a safe, robust and scalable synthesis. While the
material is commercially available, it is expensive, available in
only gram quantities, and although processes have been
reported, none are convenient to carry out on a large scale.
Herein we report development of a robust, practical and scalable
process for the preparation of 1.
Figure 2. Selective alkylation approach to 4-amino-1,3-dim-
ethylpyrazole.
Adopting the AADMA approach towards preparation of 1,
we successfully generated a mixture of 1,3- and 1,5-dimeth-
ylpyrazole, 2 and 2a, largely free of byproduct. The ratio of
1,3- to 1,5- regioisomers was 2.5:1 (1H NMR analysis).3 Having
isolated the crude reaction mixture and demonstrated through
user trial that the crude mixture of isomers did not lead to
isolation of 1 in the required isomeric purity, we turned our
attention toward purification strategies. The reported boiling
points4 of 1,3-dimethylpyrazole and 1,5-dimethylpyrazole in-
dicated that fractional distillation of the desired isomer might
be possible. Although enrichment of the desired regioisomer
was observed, isolation of isomerically pure material was not
possible in our hands by distillation alone. Nevertheless,
distillation of the crude reaction mixture under reduced pressure
(50-60 °C @ 45 mmHg) allowed efficient separation of a
mixture of 1,3- and 1,5-dimethylpyrazoles, free from residual
starting materials and water. The ratio of this purified pyrazole
fraction (1,3- to 1,5-) was found to be 2.8:1.0. Subsequent
distillation of the purified mixture of pyrazoles at ambient
pressure (138-143 °C @ 760 mmHg), through a packed bed
allowed significant enrichment of the mixture to an isomeric
purity level of >95% (1H NMR analysis). Processing of the
enriched isomeric mixture through user trial of the subsequent
nitration step gave rise to crystalline material which afforded
the possibility of further regioisomeric upgrade Via recrystal-
lisation (4:1, methyl tert-butyl ether/heptanes) to >99.0%.
Further investigations revealed that isomeric purity of the
pyrazole mixture must be >85% to allow isolation of >99.0%
(GC analysis) isomerically pure nitro compound, 3. During
development of a nitration procedure suitable for preparation
Results and Discussion
Initial attempts toward preparation of 1 were based on
methylation1 of the commercially available 3-methylpyrazole
(Figure 2). Although the desired regioisomer was formed, the
synthesis was unsuitable for the following reasons: (1) Reactions
failed to go to completion; (2) large proportions of regioisomer
were produced; (3) several byproduct were generated over the
course of the reaction.
Given the lack of success encountered using this route, we
turned our attention to methodology that would construct the
pyrazole ring. Previous reports2 indicated that reaction of methyl
hydrazine and acetylacetaldehyde dimethylacetal (AADMA)
gives a mixture of regioisomers. However, isolation of the
required 1,3 isomer was achieved Via crystallisation of the
picrate salt. Due to the inherent stability issues surrounding
picrates, an alternative mode of purification was necessary.
* Authors for correspondence. E-mail: stephen.graham@sial.com;
peter.brown@sial.com; gair.ford@astrazeneca.com.
† SAFC Pharma.
‡ AstraZeneca.
(1) Plate, R.; Plaum, M. J. M.; de Boer, T.; Andrews, J. S.; Rae, D. R.;
Gibson, S. Bioorg. Med. Chem. 1996, 4, 227. (a) Padwa, A.; Filip-
kowski, M. A.; Kline, D. N.; Murphree, S. S.; Yeske, P. E. J. Org.
Chem. 1993, 58, 2061. Yang, J.; Gharagozloo, P.; Yao, J.; Ilyin, V. I.;
Carter, R. B.; Nguyen, P.; Robledo, S.; Woodward, R. M.; Hogenkamp,
D. J. J. Med. Chem. 2004, 47, 1547. (c) Papesch, V.; Dodson, R. M. J.
Org. Chem. 1965, 30, 199.
(2) Burness, D. M. J. Org. Chem. 1956, 21, 97. Elguero, J.; Jacquier, R.;
Tarrago, G.; Tien Duc, H. C. N. Bull. Soc. Chim. Fr. 1965, 293.
(3) Holzer, W. Tetrahedron 1991, 47, 1393.
(4) Butler, A. J. Org. Chem. 1972, 37, 215.
242
•
Vol. 14, No. 1, 2010 / Organic Process Research & Development
10.1021/op900296p 2010 American Chemical Society
Published on Web 12/28/2009